 |
|
Recurrent Cardiac Events in Survivors of Ventricular Fibrillation or TachycardiaImplications for Driving Restrictions
Greg C. Larsen, MD;
Melody R. Stupey, MD;
Charles G. Walance;
Karen K. Griffith, RN, ANP;
Joel E. Cutler, MD;
Jack Kron, MD;
John H. McAnulty, MD
JAMA. 1994;271(17):1335-1339.
Abstract
| |
Objective.
—To determine when survivors of ventricular tachycardia (VT) or ventricular fibrillation (VF) might most safely return to driving.
Design.
—Consecutive case series of 501 VT and VF survivors discharged alive between August 1978 and October 1989 and followed from 0 to 117 months (mean, 26 months).
Setting.
—Cardiac arrhythmia service of a university hospital.
Patients.
—The study group comprised 290 consecutive patients with sustained VT and 211 patients with VF who underwent electrophysiological studies and were discharged alive (78% male; mean age, 59 years). The mean ejection fraction (available in 338 patients) was 0.42.
Interventions.
—Antiarrhythmic drug testing for all patients was guided by serial electrophysiological testing. Overall, 227 patients (45%) were discharged on conventional antiarrhythmic agents, 115 (23%) on amiodarone, 39 (8%) received an implantable defibrillator, and 120 (24%) received no specific antiarrhythmic therapy.
Main Outcome Measures.
—Main outcomes included any event that could hamper a patient's ability to operate a motor vehicle. Specifically, these events included recurrent VF, poorly tolerated, hemodynamically unstable VT, syncope, sudden cardiac death, and implantable defibrillator discharge.
Results.
—Event risks were assessed during the first year after hospital discharge because that is when most patients decide whether to begin driving again. The 1-year outcome event rate for all 501 patients was 17%. Three distinct periods of risk were identified. The monthly hazard rate was highest in the first month after hospital discharge (4.22% per month), intermediate in months 2 through 7 (1.81% per month), and lowest in months 8 through 12 (0.63% per month). The 191 patients for whom no successful conventional antiarrhythmic drug could be found during electrophysiological testing experienced a persistently high monthly event risk (1.6%) during months 8 through 12.
Conclusions.
—All survivors of VT or VF should refrain from driving during the first month after hospital discharge when the hazard for events that could impair their ability to drive is greatest. Our data would support restricting driving for most patients until the eighth month after hospital discharge, when risk becomes lowest. Restriction might be lengthened in patients for whom electrophysiological testing finds no satisfactory conventional antiarrhythmic agent because their risk remains higher than average even after 7 months. Individualized recommendations should be allowed because the accident rate for patients who actually suffer sudden death is low.
(JAMA. 1994;271:1335-1339)
Author Affiliations
From the Cardiology Section, Portland Veterans Affairs Medical Center (Dr Larsen), and the Arrhythmia Service, Cardiology Division, Department of Medicine, Oregon Health Sciences University, Portland (Drs Larsen, Cutler, Kron, and McAnulty, Mr Walance, and Ms Griffith). Dr Stupey was a medical student at Oregon Health Sciences University at the time of this study and is now with the Department of Psychiatry, University of Texas-San Antonio. Dr Cutler is now with Maine Cardiology Associates, Portland.
Footnotes
Reprint requests to Cardiology Section 111-B, Portland Veterans Affairs Medical Center, Portland, OR 97201 (Dr Larsen).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Syncope While Driving: Clinical Characteristics, Causes, and Prognosis
Sorajja et al.
Circulation 2009;120:928-934.
ABSTRACT
| FULL TEXT
Syncope While Driving: How Safe Is Safe?
Curtis and Epstein
Circulation 2009;120:921-923.
FULL TEXT
Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators
Task force members et al.
Europace 2009;11:1097-1107.
ABSTRACT
| FULL TEXT
Management of Implanted Cardiac Defibrillators During Eye Surgery
Rozner
Anesth. Analg. 2008;106:671-672.
FULL TEXT
Driving and Implantable Cardioverter-Defibrillator Shocks for Ventricular Arrhythmias: Results From the TOVA Study
Albert et al.
J Am Coll Cardiol 2007;50:2233-2240.
ABSTRACT
| FULL TEXT
Addendum to "Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/ Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology" Public Safety Issues in Patients With Implantable Defibrillators A Scientific Statement From the American Heart Association and the Heart Rhythm Society
Epstein et al.
Circulation 2007;115:1170-1176.
ABSTRACT
| FULL TEXT
Resumption of Driving after Life-Threatening Ventricular Tachyarrhythmia
Akiyama et al.
NEJM 2001;345:391-397.
ABSTRACT
| FULL TEXT
Driving after Ventricular Arrhythmias
Smith
NEJM 2001;345:451-452.
FULL TEXT
Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions
Freedberg et al.
J Am Coll Cardiol 2001;37:1910-1915.
ABSTRACT
| FULL TEXT
Current Status of the Implantable Cardioverter-Defibrillator
Gollob and Seger
Chest 2001;119:1210-1221.
ABSTRACT
| FULL TEXT
Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology
Epstein et al.
Circulation 1996;94:1147-1166.
FULL TEXT
WHEN IS IT SAFE FOR SURVIVORS OF CARDIAC ARREST TO DRIVE?
JWatch General 1994;1994:3-3.
FULL TEXT
|
